September 30, 2020—CBSET Inc., a not-for-profit translational research institute, announced the publication of a preclinical study, “Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients,” by Abraham R. Tzafriri, PhD, et al, online ahead of print in the Journal of Biomaterials.
“These preclinical studies transform our understanding of how drug coated balloons deliver drug to the artery and why there is no class effect, while also providing tools for understanding the role of tissue stiffening with disease. The combination of mechanistic insight with predictive modeling can help accelerate development of new technologies such as those including […]
LEXINGTON, MA — September 23, 2020 — CBSET Inc., a not-for-profit translational research institute, announced today that the company and its partner, CILcare, a leading CRO specializing in hearing disorders, have been nominated to receive a prestigious Prix Galien MedStartUp award for their collaboration in fighting hearing loss; the collaborators are nominated in the category […]
COVID-19 has significantly and adversely affected preclinical research and clinical trials across the universe of life science companies as a result of the suspension of elective procedures in the U.S. and globally, as well as the challenges posed by travel bans, the furlough of or requirement that clinical study personnel work remotely, restrictions on access […]
Montpellier, France, and Lexington, MA — September 3rd, 2020 — CILcare, world leading CRO specialized in the field of hearing, announced today that Dr. Marie-Pierre PASDELOU, CILcare’s co-founder and current Chief Development Officer, is taking over CILcare’s Regulatory Affairs and Quality Department as Chief Regulatory Officer. In parallel to offering CILcare’s sponsors strategic and operational […]
Montpellier, France, and Lexington, MA — June 15, 2020 — CILcare, world leading CRO entirely specialized in the field of hearing disorders, announces a strategic partnership with the start-up Vertidiag, a company specialized in balance disorders. By combining their unique know-how, CILcare and Vertidiag can propose a complete service offering to identify and develop therapeutic solutions […]
LEXINGTON, MA, May 19, 2020 — CBSET Inc., a not-for-profit translational research institute, announced today that its partner, CILcare, a leading CRO specializing in hearing disorders, has promoted Dr. Cyrille Sage to Director of CILcare’s U.S. operations. In his new role, Dr. Sage will be responsible for overseeing all operations performed at the joint CBSET-CILcare facility […]
LEXINGTON, MA, April 27, 2020 — CBSET Inc., a not-for-profit translational research institute, announced today that its partner, CILcare, a leading CRO specializing in hearing disorders, has promoted Dr. Wahid Awad to Chief Business Officer (CBO); and, the company further announced that Dr. Awad has been elected to its Board of Directors. Previously, Dr. Awad […]
“Auditory research studies are typically performed using rodent models. Yet, some studies may require a larger species with middle and inner ear anatomy more similar to humans,” said Misty Williams-Fritze, DVM, MS, DACLAM, PhD, and Cyrille Sage, PhD, co-lead researchers LEXINGTON, MA, Jan. 23, 2020 — — CBSET Inc., a not-for-profit translational research institute, announced […]
LEXINGTON, MA, Oct. 24, 2019 — CBSET Inc., a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that its co-founder, president and chief executive officer, Peter Markham, has been named ‘2019 Biomedical Research Business Leader’ by the Massachusetts Society for Medical Research (MSMR). He will be honored at a […]